Xuanzhu Biopharmaceutical (2575) Announces Electronic Dissemination of Corporate Communications

Bulletin Express11-20

On 21 November 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) released an announcement outlining its adoption of electronic dissemination for corporate communications in accordance with Rule 2.07 of The Stock Exchange of Hong Kong Limited’s Listing Rules. This follows the expansion of the paperless listing regime, which took effect on 31 December 2023.

The announcement states that English and Chinese versions of all future corporate communications, including annual reports, interim reports, meeting notices, listing documents, circulars, and proxy forms, will be available on both the company’s official website (www.xuanzhubio.com) and the HKExnews website (www.hkexnews.hk). Shareholders are advised to proactively monitor these websites for forthcoming publications.

Non-registered shareholders are encouraged to work with their respective intermediaries (such as banks, brokers, custodians, or nominees) to provide an up-to-date email address. A request to receive printed versions can be made by submitting the relevant reply form or by contacting the company’s H Share Registrar (Computershare Hong Kong Investor Services Limited), including a name, postal address, and the request for physical copies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114585748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114585748","market":"hk","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical (2575) Announces Electronic Dissemination of Corporate Communications","media":"Bulletin Express","content":"<p>On 21 November 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) released an announcement outlining its adoption of electronic dissemination for corporate communications in accordance with Rule 2.07 of The Stock Exchange of Hong Kong Limited’s Listing Rules. This follows the expansion of the paperless listing regime, which took effect on 31 December 2023.</p>\n<p>The announcement states that English and Chinese versions of all future corporate communications, including annual reports, interim reports, meeting notices, listing documents, circulars, and proxy forms, will be available on both the company’s official website (www.xuanzhubio.com) and the HKExnews website (www.hkexnews.hk). Shareholders are advised to proactively monitor these websites for forthcoming publications.</p>\n<p>Non-registered shareholders are encouraged to work with their respective intermediaries (such as banks, brokers, custodians, or nominees) to provide an up-to-date email address. A request to receive printed versions can be made by submitting the relevant reply form or by contacting the company’s H Share Registrar (Computershare Hong Kong Investor Services Limited), including a name, postal address, and the request for physical copies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical (2575) Announces Electronic Dissemination of Corporate Communications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical (2575) Announces Electronic Dissemination of Corporate Communications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-20 16:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 21 November 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) released an announcement outlining its adoption of electronic dissemination for corporate communications in accordance with Rule 2.07 of The Stock Exchange of Hong Kong Limited’s Listing Rules. This follows the expansion of the paperless listing regime, which took effect on 31 December 2023.</p>\n<p>The announcement states that English and Chinese versions of all future corporate communications, including annual reports, interim reports, meeting notices, listing documents, circulars, and proxy forms, will be available on both the company’s official website (www.xuanzhubio.com) and the HKExnews website (www.hkexnews.hk). Shareholders are advised to proactively monitor these websites for forthcoming publications.</p>\n<p>Non-registered shareholders are encouraged to work with their respective intermediaries (such as banks, brokers, custodians, or nominees) to provide an up-to-date email address. A request to receive printed versions can be made by submitting the relevant reply form or by contacting the company’s H Share Registrar (Computershare Hong Kong Investor Services Limited), including a name, postal address, and the request for physical copies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1114585748","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114585748","pubTimestamp":1763628658,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 21 November 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) released an announcement outlining its adoption of electronic dissemination for corporate communications in accordance with Rule 2.07...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物制药(2575)公布以电子方式发放企业通讯","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"On 21 November 2025, Xuanzhu Biopharmaceutical Co., Ltd. (2575) released an announcement outlining its adoption of electronic dissemination for corporate communications in accordance with Rule 2.07 of The Stock Exchange of Hong Kong Limited’s Listing Rules. This follows the expansion of the paperless listing regime, which took effect on 31 December 2023.\nThe announcement states that English and Chinese versions of all future corporate communications, including annual reports, interim reports, meeting notices, listing documents, circulars, and proxy forms, will be available on both the company’s official website (www.xuanzhubio.com) and the HKExnews website (www.hkexnews.hk). Shareholders are advised to proactively monitor these websites for forthcoming publications.\nNon-registered shareholders are encouraged to work with their respective intermediaries (such as banks, brokers, custodians, or nominees) to provide an up-to-date email address. A request to receive printed versions can be made by submitting the relevant reply form or by contacting the company’s H Share Registrar (Computershare Hong Kong Investor Services Limited), including a name, postal address, and the request for physical copies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114585748","isCrawlerRequest":true}